Phaseline

Companies › Tarsus Pharmaceuticals

Tarsus Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease, Ophthalmology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TP-05 (lotilaner)
Isoxazoline ectoparasiticide; potassium channel blocker
–Phase 2Lyme DiseaseOct 2027
TP-06–Phase 2Persistent Corneal Epithelial DefectJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07562087TP-05 (lotilaner)Phase 2Lyme DiseaseInfectious diseaseOct 2027
NCT07886268TP-06Phase 2Persistent Corneal Epithelial DefectOphthalmologyJul 2028

From the company's SEC filings

Cash and short-term investments of $310m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bausch & Lomb Alimera Sciences Vantage Biosciences Hyundai Bioscience Sunhawk Vision Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.